SK7292002A3 - Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4 - Google Patents

Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4 Download PDF

Info

Publication number
SK7292002A3
SK7292002A3 SK729-2002A SK7292002A SK7292002A3 SK 7292002 A3 SK7292002 A3 SK 7292002A3 SK 7292002 A SK7292002 A SK 7292002A SK 7292002 A3 SK7292002 A3 SK 7292002A3
Authority
SK
Slovakia
Prior art keywords
drug
dose
pharmaceutical composition
controlled release
pde4
Prior art date
Application number
SK729-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Robert D Murdoch
Theodore J Torphy
Barry D Zussman
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of SK7292002A3 publication Critical patent/SK7292002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SK729-2002A 1999-10-29 2000-10-26 Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4 SK7292002A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02
PCT/US2000/029453 WO2001032165A1 (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor

Publications (1)

Publication Number Publication Date
SK7292002A3 true SK7292002A3 (en) 2002-12-03

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
SK729-2002A SK7292002A3 (en) 1999-10-29 2000-10-26 Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4

Country Status (29)

Country Link
US (1) US20030212112A1 (es)
EP (1) EP1225884A4 (es)
JP (1) JP2003513038A (es)
KR (1) KR20020050249A (es)
CN (1) CN1387433A (es)
AP (1) AP2002002446A0 (es)
AR (1) AR026254A1 (es)
AU (1) AU772909B2 (es)
BG (1) BG106623A (es)
BR (1) BR0015039A (es)
CA (1) CA2389293A1 (es)
CO (1) CO5271676A1 (es)
CZ (1) CZ20021443A3 (es)
DZ (1) DZ3249A1 (es)
EA (1) EA200200502A1 (es)
HK (1) HK1049105A1 (es)
HU (1) HUP0203682A3 (es)
IL (1) IL148813A0 (es)
MA (1) MA25562A1 (es)
MX (1) MXPA02004220A (es)
NO (1) NO20021937L (es)
NZ (1) NZ518002A (es)
OA (1) OA12078A (es)
PE (1) PE20011004A1 (es)
PL (1) PL355262A1 (es)
SK (1) SK7292002A3 (es)
TR (1) TR200201150T2 (es)
UY (1) UY26422A1 (es)
WO (1) WO2001032165A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CN1655823B (zh) * 2002-05-28 2010-05-26 尼科梅德有限责任公司 局部应用的药物制剂
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2004096274A1 (ja) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
KR101763440B1 (ko) * 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
CO5271676A1 (es) 2003-04-30
IL148813A0 (en) 2002-09-12
HUP0203682A3 (en) 2003-10-28
UY26422A1 (es) 2001-07-31
NZ518002A (en) 2004-01-30
KR20020050249A (ko) 2002-06-26
MA25562A1 (fr) 2002-10-01
EP1225884A4 (en) 2005-06-15
HK1049105A1 (zh) 2003-05-02
EA200200502A1 (ru) 2002-10-31
MXPA02004220A (es) 2002-10-17
PE20011004A1 (es) 2001-09-28
OA12078A (en) 2003-05-28
AR026254A1 (es) 2003-02-05
CZ20021443A3 (cs) 2003-01-15
DZ3249A1 (fr) 2001-05-10
AU1344501A (en) 2001-05-14
EP1225884A1 (en) 2002-07-31
BG106623A (bg) 2003-02-28
US20030212112A1 (en) 2003-11-13
WO2001032165A1 (en) 2001-05-10
PL355262A1 (en) 2004-04-05
BR0015039A (pt) 2002-06-25
HUP0203682A2 (hu) 2003-04-28
JP2003513038A (ja) 2003-04-08
AU772909B2 (en) 2004-05-13
CN1387433A (zh) 2002-12-25
TR200201150T2 (tr) 2002-09-23
NO20021937D0 (no) 2002-04-24
AP2002002446A0 (en) 2002-03-31
NO20021937L (no) 2002-05-30
CA2389293A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
JP4020863B2 (ja) アムロジピン及びアトルバスタチンの医薬組成物
SK7292002A3 (en) Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4
US20070197602A1 (en) Combined pharmaceutical composition
US6511985B1 (en) Combination of cerivastatin and fibrates
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
US20230018600A1 (en) Controlled release formulations comprising drotaverine or salt thereof
CZ20013025A3 (cs) Prostředek s řízeným uvolňováním pro léčbu COPD
KR101414814B1 (ko) 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법
EP1741431B1 (en) The combination for treating hyperlipemia
WO2005013940A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
WO2019145926A1 (en) Stable thiamine containing pharmaceutical formulations
ZA200203349B (en) Method for administering a phosphodiesterase 4 inhibitor.
AU2003254428B2 (en) Stable controlled release pharmaceutical compositions containing Fenofibrate and Pravastatin
JP2005289904A (ja) 医薬組成物
MXPA01006136A (es) Combinacion de cervastatina y fibratos
KR20030070594A (ko) 암로디핀 말레에이트를 포함하는 약학 조성물
AU2004201503A1 (en) Controlled Release Formulation for Treating COPD
MXPA01008523A (es) Formulacion de liberacion controlada para tratar una enfermedad pulmonar obstructiva cronica